Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.
Obese patients with type 2 diabetes who receive treatment intensification with liraglutide may have better glycemic control than those given basal insulin, researchers report.
Specialist physicians and antidiabetic medications reported to confer cardiovascular benefit are being underutilized by patients with type 2 diabetes and cardiovascular disease, US study data show.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.
What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.
The authors report the case of a 36-year-old Japanese male patient with Prader–Willi Syndrome who was treated with a sodium-glucose cotransporter-2 inhibitor to improve glycemic control.